Source: Eur Respir J 2015; 45: 1512-1513
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Loebinger Michael R., Pozniak Anton. Screening for latent tuberculosis before tumour necrosis factor antagonist therapy. Eur Respir J 2015; 45: 1512-1513

Member's Comments

No comment yet.

Related content which might interest you: Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Tuberculosis and tumor necrosis factor alpha antagonist: Our experience Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 Using an interferon-γ assay for the diagnosis of tuberculosis infection before using tumor necrosis factor-α blockers Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease Year: 2007 A screening for latent tuberculosis infection among candidates to anti-tumor necrosis factor-alpha agents using a whole blood interferon-gamma test Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease Year: 2008 Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Latent tuberculosis screening and entering antibody therapy monoclonares against tumor necrosis factor Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016 The levels of tumour necrosis factor-alpha and interleukin-1 in newly diagnosed and multi drug resistant tuberculosis Source: Annual Congress 2004 - Clinical and diagnostic features of tuberculosis Year: 2004 Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008 Expression levels of membrane-bound tumor necrosis factor alpha receptors in active tuberculosis and healthy individuals Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 An evaluation of the use of a negative interferon gamma release assay for tuberculosis screening before TNF antagonist therapy Source: Eur Respir J 2014; 44: 1369-1372 Year: 2014 Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002 Follow up results of patients receiving anti tumor necrosis antagonists and evaluation of risk of tuberculosis Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009